Dr. Lior Shaltiel reports

NUREXONE'S EXOSOMES SHOW STRONGER HEALING POTENTIAL THAN INDUSTRY STANDARD

An independent study showed that exosomes produced by Nurexone Biologic Inc. outperformed a recognized commercial industry standard in areas that strongly support key healing tasks including nerve repair, wound repair, calming the immune system and rebuilding tissue. This first independent analysis highlighted the broad potential of Nurexone's exosomes for both therapeutic and aesthetics markets.

"This data confirms that the naive exosomes that will be manufactured by our U.S. subsidiary, ExoTOP Inc. (ExoTOP), will carry a strong regenerative and therapeutic punch. Delivering more than twice the wound-healing signals than the industry benchmark suggests applications in aesthetic skin rejuvenation, wound care and orthopedic tissue repair," said Jacob Licht, chief executive officer of ExoTOP. "As we scale production in the United States with our patent-pending 3-D production process, ExoTOP is expected to generate multiple revenue streams and provide high-performance exosomes to partners across regenerative medicine."

"Our exosomes carry complex cargo with diverse therapeutic potential, simultaneously being effective in neuroprotection and reduction in inflammation," said Dr. Tali Kizhner, director of research and development of Nurexone Biologic. "This combination is especially powerful in the nervous system, where inflammation usually prevents healing. The benchmarking analysis confirms that our exosomes naturally carry a significant amount of the molecular signals needed to create the conditions required for meaningful nerve regeneration."

TAmiRNA, an ISO13485-certified molecular-diagnostics laboratory, performed a comprehensive analysis of the EV microRNA cargo of Nurexone's exosomes and compared the results with benchmark exosomes from a commercial reference source. Based on TAmiRNA's data, bioinformatic analyses showed that Nurexone's exosomes are enriched with microRNAs that support key healing tasks.

Importantly, these exosomes were produced from Nurexone's proprietary master cell bank, whose cells are maintained under rigorously controlled environment ensuring that every production batch delivers high performance exosomes. This reproducibility is essential for clinical translation and future patient use.

The results provide strong, third party validation of Nurexone's core technology and highlight its potential across a broad range of regenerative-medicine applications.

About TAmiRNA GmbH

Vienna-based TAmiRNA is an ISO13485-certified molecular-diagnostics laboratory whose CE-marked biomarker kits and miND small-RNA sequencing platform provide industry-leading, ISEV-compliant exosome analytics. Its extensive extracellular-vesicle reference database and bench-to-algorithm workflow deliver regulatory-grade, reproducible insights for precision-medicine programs.

About Nurexone Biologic Inc.

Nurexone Biologic is a TSX Venture Exchange-, OTCQB- and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multibillion-dollar markets. Regulatory milestones, including obtaining the orphan drug designation, facilitates the road map toward clinical trials in the United States and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. Nurexone has established Exo-Top Inc., a United States subsidiary, to anchor its North American activity and growth strategy.

We seek Safe Harbor.